Jay Alan Fishman, M.D.
|Title||Professor of Medicine|
|Institution||Massachusetts General Hospital|
|Address||Massachusetts General Hospital|
Infectious Disease, GRJ 504
55 Fruit St
Boston MA 02114
(login for email)
|1971||National Merit Scholar|
|1978 - 1979||Research Honor Prize|
|1979||Special Student, Clinical Immunology|
|1983||Travel Grant Award|
|1986 - 1987||American Foundation for AIDS Research Research Award|
|1987||Fellowship, MacArthur Foundation for Molecular Parasitology|
|1988 - 1989||Fellowship|
|1989||Principal Investigator |
|1991 - 1992||American Lung Association Research Award|
|1999||Power of Distinction|
|2002||Fujisawa Clinical Career Achievement Award|
|2004 - 2005||President|
|2008||Roche Award for Transplant Infectious Disease|
|2009||Martin Research Prize for Excellence in Clinical Research |
|2014||AST Senior Career Achievement Award in Clinical Transplantation|
This laboratory has focused on the molecular pathogenesis of infections in immunocompromised hosts. We have isolated and cloned the major surface antigens of the fungal pathogen Pneumocystis carinii. We have studied pathogenesis of infections by the porcine endogenous retrovirus and other porcine viruses to prevent infection in future pig-to-human xenotransplantation, as a model for organ-donor-derived infections. The virus (PERV) has been cloned and quantitative assays developed for this potential pathogen. This approach has been used nationally and internationally in the development of guidelines for screening of organ donors in solid organ transplantation and xenotransplantation including the FDA Advisory Panel on Xenotransplantation, guidelines for Harvard Medical School, US Public Health Service, Health Canada, Institute of Medicine, and World Health Organization.
Clinical investigation has been an outgrowth of the Transplant Infectious Disease Program. Trials of innovative therapies for Pneumocystis infection (atovaquone) in stem cell and solid organ transplantation and of bioavailability of new antiviral agents (ganciclovir) grew directly out of clinical need for such therapies. More recently, we have developed clinical protocols for the national multicenter Clinical Trials in Organ Transplantation to monitor viral infections using novel mutiplexed viral molecular assays, approaches to antimicrobial prophylaxis (ganciclovir, valganciclovir) and therapy (posaconazole) in immunosuppressed hosts, for the harmonization of laboratory assays for viral infections across multiple assay platforms at multiple clinical centers, and for antibody responses to vaccination following heart and kidney transplantation. We have also participated in animal and human trails of the induction of immune tolerance for organ transplantation.
The research activities and funding listed below are automatically derived from
NIH ExPORTER and other sources, which might result in incorrect or missing items.
to make corrections and additions.
P01AI045897 (SYKES, MEGAN)Sep 1, 2000 - Jul 31, 2017NIH/NIAID
A Tolerance Approach to Xenotransplantation
Role: Co-Principal Investigator
R01HL051957 (FISHMAN, JAY A.)Sep 30, 1993 - Aug 31, 1999NIH/NHLBI
ALVEOLAR MACROPHAGE RESPONSE TO MYCOBACTERIAL CELL WALL
Role: Principal Investigator
K08HL001916 (FISHMAN, JAY A.)Jul 1, 1987 - Jun 30, 1992NIH/NHLBI
Role: Principal Investigator
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For demographic and contact information changes only, HMS/HSDM faculty should contact Human Resources at human_resourceshms.harvard.edu.
Click the "See All" links for more information and interactive visualizations!
People who are also in this person's primary department.